Dupilumab for treating Chronic Spontaneous Urticaria in people aged 12 years and older after 1 previous treatment

Dupilumab is in clinical development for the treatment of chronic spontaneous urticaria for people who still have symptoms despite previous treatment. Urticaria is a skin disorder where red, raised, itchy rashes appear on the skin. Urticaria is considered chronic once symptoms have been present for six weeks or longer and appear almost daily. Spontaneous urticaria occurs when there is no clear trigger that brings on urticaria symptoms. People who do not respond to treatment with antihistamines or a biological therapy known as omalizumab currently have limited further treatment options.
Dupilumab is a human monoclonal